Chronic binge alcohol consumption does not diminish effectiveness of continuous antiretroviral suppression of viral load in simian immunodeficiency virus-infected macaques

Alcoholism: Clinical and Experimental Research

Volumn 38, Issue 9, 2014, Pages 2335-2344

  Molina, Patricia E ^a,b   Amedee, Angela M ^a   Veazey, Ron ^a   Dufour, Jason ^a   Volaufova, Julia ^a   Bagby, Gregory J ^a,b   Nelson, Steve ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alcohol; Antiretroviral; Rhesus; Simian immunodeficiency virus; Toxicity

Indexed keywords

ADENINE; CREATININE; EMTRICITABINE; PROTEIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ANTIRETROVIRUS AGENT;

ALCOHOL CONSUMPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL THERAPY; ARTICLE; BINGE DRINKING; CONTROLLED STUDY; COUNSELING; CREATININE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; INOCULATION; KIDNEY FUNCTION; MACACA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; CHRONIC DISEASE; COMPLICATION; DRUG EFFECTS; IMMUNOLOGY;

ANIMALIA; MACACA; MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS;

ANIMALS; ANTI-RETROVIRAL AGENTS; BINGE DRINKING; CHRONIC DISEASE; MACACA MULATTA; MALE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL LOAD;

EID: 84925933930     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/acer.12507     Document Type: Article

References (56)

1. Arthur LO, Gilden RV, Marx PA, Gardner MB (1986) Simian acquired immunodeficiency syndrome. Prog Allergy 37:332-352.
2. Azar MM, Springer SA, Meyer JP, Altice FL (2010) A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend 112:178-193.
3. Bagby GJ, Stoltz DA, Zhang P, Kolls JK, Brown J, Bohm RP, Rockar R, Purcell J, Murphey-Corb M, Nelson S (2003) The effect of chronic binge ethanol consumption on the primary stage of SIV infection in rhesus macaques. Alcohol Clin Exp Res 27:495-502.
4. Barbaro G (2006) Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk. Am J Ther 13:248-260.
5. Baum MK, Rafie C, Lai S, Sales S, Page JB, Campa A (2010) Alcohol use accelerates HIV disease progression. AIDS Res Hum Retroviruses 26:511-518.
6. Braithwaite RS, Conigliaro J, Roberts MS, Shechter S, Schaefer A, McGinnis K, Rodriguez MC, Rabeneck L, Bryant K, Justice AC (2007) Estimating the impact of alcohol consumption on survival for HIV+ individuals. AIDS Care 19:459-466.
7. Cassol E, Misra V, Holman A, Kamat A, Morgello S, Gabuzda D (2013) Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors. BMC Infect Dis 13:203.
8. Centers for Disease Control and Prevention (CDC) (2011) Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep 60:65-68.
9. Centers for Disease Control and Prevention (CDC) (2012) Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR Morb Mortal Wkly Rep 61:586-589.
10. Centers for Disease Control and Prevention (CDC) (2013) Monitoring selected national HIV prevention and care objectives by using HIV surveillance data-United States and 6 dependent areas-2011. HIV Surveillance Supplemental Report 18 (No. 5): 1-47. Available at: http://www.cdc.gov/hiv/library/reports/surveillance/pastIssues.html#panel1. Accessed March 12, 2014.
11. Centers for Disease Control and Prevention (CDC) (2014) Alcohol and public health. Fact sheet-binge drinking. Available at: http://www.cdc.gov/alcohol/fact-sheets/binge-drinking.htm. Accessed May 2, 2014.
12. Chander G, Himelhoch S, Moore RD (2006) Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy. Drugs 66:769-789.
13. Cook RL, Sereika SM, Hunt SC, Woodward WC, Erlen JA, Conigliaro J (2001) Problem drinking and medication adherence among persons with HIV infection. J Gen Intern Med 16:83-88.
14. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M (2010) Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 51:496-505.
15. Do HM, Dunne MP, Kato M, Pham CV, Nguyen KV (2013) Factors associated with suboptimal adherence to antiretroviral therapy in Viet Nam: a cross-sectional study using audio computer-assisted self-interview (ACASI). BMC Infect Dis 13:154.
16. Ferguson CS, Miksys S, Palmour RM, Tyndale RF (2012) Differential effects of nicotine treatment and ethanol self-administration on CYP2A6, CYP2B6 and nicotine pharmacokinetics in African green monkeys. J Pharmacol Exp Ther 343:628-637.
17. Ferguson CS, Miksys S, Palmour RM, Tyndale RF (2013) Ethanol self-administration and nicotine treatment induce brain levels of CYP2B6 and CYP2E1 in African green monkeys. Neuropharmacology 72:74-81.
18. Gallant JE, Parish MA, Keruly JC, Moore RD (2005) Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 40:1194-1198.
19. Galvan FH, Bing EG, Fleishman JA, London AS, Caetano R, Burnam MA, Longshore D, Morton SC, Orlando M, Shapiro M (2002) The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: results from the HIV Cost and Services Utilization Study. J Stud Alcohol 63:179-186.
20. García-Lerma JG, Cong ME, Mitchell J, Youngpairoj AS, Zheng Q, Masciotra S, Martin A, Kuklenyik Z, Holder A, Lipscomb J, Pau CP, Barr JR, Hanson DL, Otten R, Paxton L, Folks TM, Heneine W (2010) Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med 2:14ra14.
21. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ (2011) The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 52:793-800.
22. Gardner MB, Luciw PA (1988) Simian immunodeficiency viruses and their relationship to the human immunodeficiency viruses. AIDS 2(Suppl 1):S3-S10.
23. + T-cell restoration and enhanced gene expression regulating mucosal repair and regeneration. J Virol 79:2709-2719.
24. Glass TR, Battegay M, Cavassini M, De Geest S, Furrer H, Vernazza PL, Hirschel B, Bernasconi E, Rickenbach M, Günthard HF, Bucher HC, Study SHC (2010) Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 54:197-203.
25. Grierson J, Koelmeyer RL, Smith A, Pitts M (2011) Adherence to antiretroviral therapy: factors independently associated with reported difficulty taking antiretroviral therapy in a national sample of HIV-positive Australians. HIV Med 12:562-569.
26. Hendershot CS, Stoner SA, Pantalone DW, Simoni JM (2009) Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr 52:180-202.
27. Hinkin CH, Hardy DJ, Mason KI, Castellon SA, Durvasula RS, Lam MN, Stefaniak M (2004) Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS 18(Suppl 1):S19-S25.
28. Jacob T, Blonigen DM, Upah R, Justice A (2013) Lifetime drinking trajectories among veterans in treatment for HIV. Alcohol Clin Exp Res 37:1179-1187.
29. Jarvis CM, Hayman LL, Braun LT, Schwertz DW, Ferrans CE, Piano MR (2007) Cardiovascular risk factors and metabolic syndrome in alcohol- and nicotine-dependent men and women. J Cardiovasc Nurs 22:429-435.
30. Kalichman SC, Amaral CM, White D, Swetsze C, Kalichman MO, Cherry C, Eaton L (2012) Alcohol and adherence to antiretroviral medications: interactive toxicity beliefs among people living with HIV. J Assoc Nurses AIDS Care 23:511-520.
31. Kalichman SC, Grebler T, Amaral CM, McNerey M, White D, Kalichman MO, Cherry C, Eaton L (2013) Intentional non-adherence to medications among HIV positive alcohol drinkers: prospective study of interactive toxicity beliefs. J Gen Intern Med 28:399-405.
32. Kosmiski L, Kuritzkes D, Lichtenstein K, Eckel R (2003) Adipocyte-derived hormone levels in HIV lipodystrophy. Antivir Ther 8:9-15.
33. Kumar S, Jin M, Ande A, Sinha N, Silverstein PS, Kumar A (2012) Alcohol consumption effect on antiretroviral therapy and HIV-1 pathogenesis: role of cytochrome P450 isozymes. Expert Opin Drug Metab Toxicol 8:1363-1375.
34. Lefevre F, O'Leary B, Moran M, Mossar M, Yarnold PR, Martin GJ, Glassroth J (1995) Alcohol consumption among HIV-infected patients. J Gen Intern Med 10:458-460.
35. Letvin NL, King NW (1990) Immunologic and pathologic manifestations of the infection of rhesus monkeys with simian immunodeficiency virus of macaques. J Acquir Immune Defic Syndr 3:1023-1040.
36. Lewis MG, Norelli S, Collins M, Barreca ML, Iraci N, Chirullo B, Yalley-Ogunro J, Greenhouse J, Titti F, Garaci E, Savarino A (2010) Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology 7:21.
37. + T cells in gut-associated lymphoid tissues in SIVmac239-infected rhesus macaques, but not resistance to rechallenge. J Med Primatol 32:201-210.
38. Lima VD, Harrigan R, Murray M, Moore DM, Wood E, Hogg RS, Montaner JS (2008) Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS 22:2371-2380.
39. Lima VD, Kerr T, Wood E, Kozai T, Salters KA, Hogg RS, Montaner JS (2014) The effect of history of injection drug use and alcoholism on HIV disease progression. AIDS Care 26:123-129.
40. Ling B, Veazey RS, Luckay A, Penedo C, Xu K, Lifson JD, Marx PA (2002) SIV(mac) pathogenesis in rhesus macaques of Chinese and Indian origin compared with primary HIV infections in humans. AIDS 16:1489-1496.
41. Miguez MJ, Shor-Posner G, Morales G, Rodriguez A, Burbano X (2003) HIV treatment in drug abusers: impact of alcohol use. Addict Biol 8: 33-37.
42. Molina PE, Lang CH, McNurlan M, Bagby GJ, Nelson S (2008) Chronic alcohol accentuates simian acquired immunodeficiency syndrome-associated wasting. Alcohol Clin Exp Res 32: 138-147.
43. Molina PE, McNurlan M, Rathmacher J, Lang CH, Zambell KL, Purcell J, Bohm RP, Zhang P, Bagby GJ, Nelson S (2006) Chronic alcohol accentuates nutritional, metabolic, and immune alterations during asymptomatic simian immunodeficiency virus infection. Alcohol Clin Exp Res 30:2065-2078.
44. Palepu A, Tyndall MW, Li K, Yip B, O'Shaughnessy MV, Schechter MT, Montaner JS, Hogg RS (2003) Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy. J Urban Health 80:667-675.
45. Panel on Antiretroviral Guidelines for Adults and Adolescents (2014) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed March 15, 2014.
46. Parsons JT, Rosof E, Mustanski B (2008) The temporal relationship between alcohol consumption and HIV-medication adherence: a multilevel model of direct and moderating effects. Health Psychol 27:628-637.
47. Samet JH, Horton NJ, Meli S, Freedberg KA, Palepu A (2004) Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems. Alcohol Clin Exp Res 28:572-577.
48. Sankar A, Wunderlich T, Neufeld S, Luborsky M (2007) Sero-positive African Americans' beliefs about alcohol and their impact on anti-retroviral adherence. AIDS Behav 11:195-203.
49. Smith MS, Foresman L, Lopez GJ, Tsay J, Wodarz D, Lifson JD, Page A, Wang C, Li Z, Adany I, Buch S, Bischofberger N, Narayan O (2000) Lasting effects of transient postinoculation tenofovir [9-R-(2-Phosphonomethoxypropyl)adenine] treatment on SHIV(KU2) infection of Rhesus macaques. Virology 277:306-315.
50. Sonenthal PD, Ratshaa B, Chimbengo G, Rantleru T, Ngoni T, Barenbaum S, Platoff R, Steenhoff AP, Gross R (2014) Baseline predictors of efavirenz-containing antiretroviral regimen adverse experiences. Pharmacoepidemiol Drug Saf 23:773-777.
51. United States (2011) Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings. H-44; DHHS publication, no. (SMA) 12-4173. U.S. Dept. of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality, Rockville, MD.
52. Valle R, Haragsim L (2006) Nephrotoxicity as a complication of antiretroviral therapy. Adv Chronic Kidney Dis 13:314-319.
53. Van Rompay KK, Durand-Gasselin L, Brignolo LL, Ray AS, Abel K, Cihlar T, Spinner A, Jerome C, Moore J, Kearney BP, Marthas ML, Reiser H, Bischofberger N (2008) Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother 52:3144-3160.
54. Van Rompay KK, Singh RP, Brignolo LL, Lawson JR, Schmidt KA, Pahar B, Canfield DR, Tarara RP, Sodora DL, Bischofberger N, Marthas ML (2004) The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters. J Acquir Immune Defic Syndr 36:900-914.
55. + T cells in gut mucosa but enhances their rapid restoration through central memory T cells. J Virol 82:4016-4027.
56. Wu ES, Metzger DS, Lynch KG, Douglas SD (2011) Association between alcohol use and HIV viral load. J Acquir Immune Defic Syndr 56: e129-e130.